Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects
Phase 1
Completed
- Conditions
- Schizophrenia
- Registration Number
- NCT00505973
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
This study is being conducted to assess the safety and tolerability of ascending multiple oral doses of SCA-136 administered to healthy Japanese male subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Adverse events, safety laboratory results, vital signs, and ECGs will be used to monitor subject safety.
- Secondary Outcome Measures
Name Time Method